AMDL Announces 2nd Quarter 2007 Operational Results
August 21 2007 - 8:15AM
PR Newswire (US)
TUSTIN, Calif., Aug. 21 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL) announced today that for the three-month period ended
June 30, 2007 the Company had net revenues of $2,413,501, an
approximate increase of 69% over the first quarter of 2007. The
Company had gross profits of $1,151,452 and incurred a net loss of
($2,264,305). Included in the loss were non-cash expenses of
approximately $2,074,112 for depreciation, common stock, warrants
and options issued. Gary Dreher, CEO of AMDL stated that, "We are
pleased by the significant growth of AMDL's business. AMDL's
subsidiary Jade Pharmaceutical, Inc, (JPI) continues to grow its
marketing and sales in the excellent Chinese marketplace. These
activities position JPI for near-term increased sales growth,
particularly during the second half of 2007." About AMDL: AMDL,
Inc., headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi and Jilin China, through its wholly owned
subsidiary Jade Pharmaceutical Inc. ("JPI"), is an international
biopharma company. AMDL together with JPI, engages in the
development, manufacture and marketing of proprietary
pharmaceutical and diagnostic products. More information about AMDL
and its products can be obtained at http://www.amdl.com/. About
Jade Pharmaceutical: JPI has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL,
through its subsidiaries, JPI currently manufactures large volume
injection fluids, tablets and other related products, holding
licenses for 133 products. It also manufactures 107 generic, over
the counter and supplemental pharmaceutical products under
certified Chinese Good Manufacturing Practice (CGMP) standards.
Forward-Looking Statements: This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those
projected in such forward-looking statements. The Company cautions
readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 VoiceMail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: Mr. Paul Knopick, AMDL Investor Relations,
+1-949-707-5365, VoiceMail: +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024